Uterine Cancer Diagnostic Testing Market 2018 Global Industry Sales, Supply, Consumption, Demand, Analysis and Forecasts to 2026
The Uterine Cancer Diagnostic Testing Market is expected to grow at a stupendous rate in the next 10 years. The healthcare industry is being driven by innovation. The very idea of “Customer is the King” is being implemented. As such, healthcare IT solutions come across as a meticulous and complex system that constitutes interconnected and large-scale systems wherein micros are being worked upon. These would be the facets of the healthcare vertical going forward.
In a recent study on the global uterine cancer diagnostic testing market, leading research firm Persistence Market Research has tracked the growth path of the global market for uterine cancer diagnostic testing over an eight year period from 2018 to 2026. The report features global market numbers and insights on the various factors driving the adoption of advanced uterine cancer diagnostic tests.
According to the report, two of the main aspects responsible for a surge in revenue in the global uterine cancer diagnostic testing market are – a rising awareness among the female population pertaining to the various diseases of the uterus, and the availability of different types of direct and combination tests to detect uterine cancer.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17005
- Roche Holdings AG
- Siemens AG
- BioMerieux SA
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17005
Persistence Market Research forecasts revenue in the global uterine cancer diagnostic testing market to reach around US$ 3.8 Bn by 2026 end, up from an estimated value of about US$ 2 Bn in 2018. The market is expected to witness a growth rate of 7.8% during the eight year period from 2018 to 2026.
Numerous Tumor Marker Tests Currently Used to Detect Uterine Cancer to Provide a Wide Window of Opportunity in the Global Market
Persistence Market Research analysis indicates that the glycoproteins CA19.9, YKL-40, CA72.4, and CA15.3 are useful markers that help in the diagnosis of patients suffering from endometrial cancer and may provide a wide opportunity as advanced and improved tumor marker tests for uterine cancer diagnostic testing in the coming years.
Early detection of endometrial cancer in women with irregular and post-menopausal bleeding (one of the early symptoms of endometrial carcinoma) is also likely to elevate the market for uterine cancer diagnostic testing. BRCA1 and BRCA2 breast cancer mutations are related to the spread of endometrial cancer in women.
Ongoing research studies that have linked uterine cancer and BRCA mutation indicate favorable outcomes for early-stage diagnosis and prevention of endometrial cancer, by suggesting a uterine diagnosis post the diagnosis of BRCA1 mutation. This is also anticipated to be a good opportunity area in the uterine cancer diagnostic testing market in the near future.
Genetics and Epigenetics Trending the Global Uterine Cancer Diagnostic Testing Market
Gene mutations are fast emerging as candidates in the carcinogenesis of endometrial carcinoma and uterine sarcoma. Gene mutations — including K-ras mutations, PTEN, and β-catenin — are being studied...
Do you already have an account? Log in here